FGFR1 and non-small cell lung carcinoma: In addition, even for the very same FGFR alteration within the same tumor type, highly different prevalence data are reported across published data: a recent meta-analysis on the frequency of FGFR1 gene amplification in NSCLC evaluating twenty-three studies (5252 patients) revealed a 10-fold difference in the prevalence, ranging from only 4.9 to up to 49% [148].